PTK2 and breast carcinoma: The upregulation of Integrin β1 and α6, as well as the activation of FAK in the mammary carcinomas may provide an important research tool for potential use of rat carcinogenesis models for preclinical evaluation FAK- and/or Integrin-signaling inhibitors as anticancer drugs.